Dana Danino1,2, Shalom Ben-Shimol1,2, Bart Adriaan van der Beek1, Noga Givon-Lavi1,2, Yonat Shemer Avni1,3, David Greenberg1,2, Daniel M Weinberger4, Ron Dagan1. 1. Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. 2. The Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer-Sheva, Israel. 3. Clinical Virology Laboratory, Soroka University Medical Center, Beer-Sheva, Israeland. 4. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Abstract
BACKGROUND: The incidence of invasive pneumococcal disease (IPD) declined during the COVID-19 pandemic. Previous studies hypothesized that this was due to reduced pneumococcal transmission resulting from nonpharmaceutical interventions. We used multiple ongoing cohort surveillance projects in children <5 years to test this hypothesis. METHODS: The first SARS-CoV-2 cases were detected in February 2020, resulting in a full lockdown, followed by several partial restrictions. Data from ongoing surveillance projects captured the incidence dynamics of community-acquired alveolar pneumonia (CAAP), nonalveolar lower respiratory infections necessitating chest X-rays (NA-LRIs), nasopharyngeal pneumococcal carriage in nonrespiratory visits, nasopharyngeal respiratory virus detection (by polymerase chain reaction), and nationwide IPD. Monthly rates (January 2020 through February 2021 vs mean monthly rates 2016-2019 [expected rates]) adjusted for age and ethnicity were compared. RESULTS: CAAP and bacteremic pneumococcal pneumonia were strongly reduced (incidence rate ratios [IRRs]: .07 and .19, respectively); NA-LRIs and nonpneumonia IPD were also reduced by a lesser magnitude (IRRs: .46 and .42, respectively). In contrast, pneumococcal carriage prevalence was only slightly reduced, and density of colonization and pneumococcal serotype distributions were similar to previous years. The decline in pneumococcus-associated disease was temporally associated with a full suppression of respiratory syncytial virus, influenza viruses, and human metapneumovirus, often implicated as co-pathogens with pneumococcus. In contrast, adenovirus, rhinovirus, and parainfluenza activities were within or above expected levels. CONCLUSIONS: Reductions in pneumococcal and pneumococcus-associated diseases occurring during the COVID-19 pandemic in Israel were not predominantly related to reduced pneumococcal carriage and density but were strongly associated with the disappearance of specific respiratory viruses.
BACKGROUND: The incidence of invasive pneumococcal disease (IPD) declined during the COVID-19 pandemic. Previous studies hypothesized that this was due to reduced pneumococcal transmission resulting from nonpharmaceutical interventions. We used multiple ongoing cohort surveillance projects in children <5 years to test this hypothesis. METHODS: The first SARS-CoV-2 cases were detected in February 2020, resulting in a full lockdown, followed by several partial restrictions. Data from ongoing surveillance projects captured the incidence dynamics of community-acquired alveolar pneumonia (CAAP), nonalveolar lower respiratory infections necessitating chest X-rays (NA-LRIs), nasopharyngeal pneumococcal carriage in nonrespiratory visits, nasopharyngeal respiratory virus detection (by polymerase chain reaction), and nationwide IPD. Monthly rates (January 2020 through February 2021 vs mean monthly rates 2016-2019 [expected rates]) adjusted for age and ethnicity were compared. RESULTS: CAAP and bacteremic pneumococcal pneumonia were strongly reduced (incidence rate ratios [IRRs]: .07 and .19, respectively); NA-LRIs and nonpneumonia IPD were also reduced by a lesser magnitude (IRRs: .46 and .42, respectively). In contrast, pneumococcal carriage prevalence was only slightly reduced, and density of colonization and pneumococcal serotype distributions were similar to previous years. The decline in pneumococcus-associated disease was temporally associated with a full suppression of respiratory syncytial virus, influenza viruses, and human metapneumovirus, often implicated as co-pathogens with pneumococcus. In contrast, adenovirus, rhinovirus, and parainfluenza activities were within or above expected levels. CONCLUSIONS: Reductions in pneumococcal and pneumococcus-associated diseases occurring during the COVID-19 pandemic in Israel were not predominantly related to reduced pneumococcal carriage and density but were strongly associated with the disappearance of specific respiratory viruses.
Authors: Alexis Rybak; Corinne Levy; François Angoulvant; Anne Auvrignon; Piotr Gembara; Kostas Danis; Sophie Vaux; Daniel Levy-Bruhl; Sylvie van der Werf; Stéphane Béchet; Stéphane Bonacorsi; Zein Assad; Andréa Lazzati; Morgane Michel; Florentia Kaguelidou; Albert Faye; Robert Cohen; Emmanuelle Varon; Naïm Ouldali Journal: JAMA Netw Open Date: 2022-06-01
Authors: You Li; Xin Wang; Dianna M Blau; Mauricio T Caballero; Daniel R Feikin; Christopher J Gill; Shabir A Madhi; Saad B Omer; Eric A F Simões; Harry Campbell; Ana Bermejo Pariente; Darmaa Bardach; Quique Bassat; Jean-Sebastien Casalegno; Giorgi Chakhunashvili; Nigel Crawford; Daria Danilenko; Lien Anh Ha Do; Marcela Echavarria; Angela Gentile; Aubree Gordon; Terho Heikkinen; Q Sue Huang; Sophie Jullien; Anand Krishnan; Eduardo Luis Lopez; Joško Markić; Ainara Mira-Iglesias; Hannah C Moore; Jocelyn Moyes; Lawrence Mwananyanda; D James Nokes; Faseeha Noordeen; Evangeline Obodai; Nandhini Palani; Candice Romero; Vahid Salimi; Ashish Satav; Euri Seo; Zakhar Shchomak; Rosalyn Singleton; Kirill Stolyarov; Sonia K Stoszek; Anne von Gottberg; Danielle Wurzel; Lay-Myint Yoshida; Chee Fu Yung; Heather J Zar; Harish Nair Journal: Lancet Date: 2022-05-19 Impact factor: 202.731
Authors: Paul R Wratil; Niklas A Schmacke; Andreas Osterman; Matthias Klein; Oliver T Keppler; Tobias Weinberger; Jochen Rech; Burak Karakoc; Mira Zeilberger; Julius Steffen; Tonina T Mueller; Patricia M Spaeth; Marcel Stern; Manuel Albanese; Hella Thun; Julia Reinbold; Benedikt Sandmeyer; Philipp Kressirer; Béatrice Grabein; Peter Falkai; Kristina Adorjan; Veit Hornung; Lars Kaderali Journal: Infection Date: 2021-08-11 Impact factor: 7.455
Authors: Anneke Steens; Mirjam J Knol; Wieke Freudenburg-de Graaf; Hester E de Melker; Arie van der Ende; Nina M van Sorge Journal: Microorganisms Date: 2022-05-05
Authors: Noga Givon-Lavi; Dana Danino; Bart Adriaan van der Beek; Amir Sharf; David Greenberg; Shalom Ben-Shimol Journal: BMC Pediatr Date: 2022-05-06 Impact factor: 2.567
Authors: Roy Burstein; Benjamin M Althouse; Amanda Adler; Adam Akullian; Elizabeth Brandstetter; Shari Cho; Anne Emanuels; Kairsten Fay; Luis Gamboa; Peter Han; Kristen Huden; Misja Ilcisin; Mandy Izzo; Michael L Jackson; Ashley E Kim; Louise Kimball; Kirsten Lacombe; Jover Lee; Jennifer K Logue; Julia Rogers; Erin Chung; Thomas R Sibley; Katrina Van Raay; Edward Wenger; Caitlin R Wolf; Michael Boeckh; Helen Chu; Jeff Duchin; Mark Rieder; Jay Shendure; Lea M Starita; Cecile Viboud; Trevor Bedford; Janet A Englund; Michael Famulare Journal: medRxiv Date: 2022-02-06
Authors: Patrick M Meyer Sauteur; Michael L Beeton; Søren A Uldum; Nathalie Bossuyt; Melissa Vermeulen; Katherine Loens; Sabine Pereyre; Cécile Bébéar; Darja Keše; Jessica Day; Baharak Afshar; Victoria J Chalker; Gilbert Greub; Ran Nir-Paz; Roger Dumke Journal: Euro Surveill Date: 2022-05